Skip to content

CTI BIOPHARMA CORP

CIK 0000891293

← back to feed
Revenue (TTM)
$56.98M
Q1 May 2023
Net Income (TTM)
−$88.96M
+5.0% YoY Q1 May 2023
EPS Diluted (TTM)
−$0.81
+25.7% YoY Q1 May 2023
Gross Margin
-0.1%
Q1 May 2023
Operating Margin
-132.4%
Q1 May 2023
Net Margin
-156.1%
Q1 May 2023
Free Cash Flow (TTM)
−$88.36M
Q1 May 2023
Cash
$24.21M
Q1 May 2023
Total Debt
$95.89M
Q1 May 2023
Shares Outstanding
131.88M sh
Q1 May 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings